Armistice Capital, LLC
Armistice Capital, LLC is a hedge fund headquartered in New York, NY. Founded in 2012, the firm manages significant assets on behalf of institutional investors and high-net-worth individuals. Armistice Capital specializes in long/short equity strategies, primarily focusing on U.S. publicly traded companies. The firm has approximately 30 employees.
Investment Strategy
Armistice Capital employs a long/short equity investment strategy with an emphasis on U.S. securities. The fund actively manages a diverse portfolio and uses derivatives, such as put options, to hedge or enhance positions. It frequently invests in sectors like pharmaceuticals and retail, with position sizes reflecting fundamental analysis and a flexible approach to market conditions.
Latest 13F Filing Activity
Armistice Capital, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 177 equity positions and 5 options positions with a total 13F market value of $6B. The fund increased holdings in Ge Healthcare Technologies I, Mcdonalds Corp., Immunitybio Inc. among other positions. Armistice Capital, LLC reduced exposure to Spectrum Brands HLDGS Inc. Ne, Simply Good Foods Co., PTC Therapeutics Inc. among others.
Top Holdings
Equity Positions (177)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
P PTCT | PTC THERAPEUTICS INC | 3.99% | $231.3M | 4,735,464 | $31.13 | $48.84 | -$45.7M |
S SUPN | SUPERNUS PHARMACEUTICALS INC | 2.62% | $151.7M | 4,812,000 | $26.36 | $31.52 | -$18.5M |
T TVTX | TRAVERE THERAPEUTICS INC | 2.27% | $131.4M | 8,876,000 | $19.90 | $14.80 | -$27.6M |
I INCY | INCYTE CORP | 1.57% | $91.0M | 1,336,000 | $59.91 | $68.10 | -$10.2M |
N NBIX | NEUROCRINE BIOSCIENCES INC | 1.47% | $85.0M | 676,024 | $126.71 | $125.69 | -$25.7M |
Options Positions (5)
| Ticker | Security | Action | Type | Notional Value | Contracts | Underlying Price | Premium Paid | Change (Contracts) | Change (Value) |
|---|---|---|---|---|---|---|---|---|---|
S SPY | SPDR S&P 500 ETF TR | — | Put | $1.51B | 24,500 | $617.85 | $425.62 | 0 | +$143.2M |
I IWM | ISHARES TR | Bought | Put | $1.51B | 70,000 | $215.79 | $191.99 | +3,000 | +$173.9M |
M MDGL | MADRIGAL PHARMACEUTICALS INC | Sold | Call | $51.4M | 1,700 | $302.64 | $331.23 | -1,300 | -$47.9M |
C CYTK | CYTOKINETICS INC | Sold | Call | $44.3M | 13,400 | $33.04 | $44.55 | -13,600 | -$64.2M |
F FIVN | FIVE9 INC | New | Call | $37.6M | 14,200 | $26.48 | $26.48 | +14,200 | +$37.6M |
Industry Allocation
Investment Team (8)
| Name | Role | Location | |
|---|---|---|---|
G Gavriel Mullokandov | Biotechnology Analyst | New York, NY , United States | |
H Harris Brown | Portfolio Manager - Consumer | New York, NY , United States | |
J Jason Glass | Managing Director | New York, NY , United States | |
 | Vice President | Ramsey, NJ , United States | |
 | Portfolio Manager | Miami, FL , United States | |
S Steven Boyd | Managing Partner | New York, NY , United States | |
 | Partner, Consumer Sector Head and Portfolio Manager | New York, NY , United States | |
K Keith Maher | Managing Director | New York, NY , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more